Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Completed 3Recruiting 2Terminated 1Active not recruiting 1

Sponsor Class

NIH 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 26Gynecologic 9Tumor-Agnostic 6Lymphoid 5Genitourinary 5Sarcoma 4Other hematologic neoplasm 4Thoracic 3Endocrine 3Dermatologic 3Other solid neoplasm 2CNS 2Breast 2Head & Neck 1

Conditions

Uveal Melanoma 2Melanoma 2

Interventions

Ipilimumab 123pembrolizumab 101Nivolumab 100aldesleukin 89Cyclophosphamide 85fludarabine phosphate 64Interleukin-2 58Dacarbazine 573-ingenyl angelate 42Vemurafenib 39Temozolomide 39Imiquimod 39trametinib 37sargramostim 37Peripheral Blood Stem Cell Transplantation 36incomplete Freund's adjuvant 35dabrafenib 32fludarabine 31Radiotherapy 31Aminolevulinic Acid 30Bevacizumab 29Carboplatin 28Whole-Body Irradiation 25Photochemotherapy 25Paclitaxel 25Filgrastim 25Biopsy 25Interferon-alpha 24Cisplatin 23Sorafenib 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × aflibercept × Dermatologic × Clear all
NCT03172299 2025-03-24

PROTECT

Centre Hospitalier Universitaire de Nice

Phase 3 Completed
57 enrolled
Dermatologic

Uveal Melanoma

NCT01258855 2019-05-10

Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 2 Completed
84 enrolled 13 charts
Dermatologic

Melanoma

NCT00450255 2018-05-24

VEGF Trap in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 2 Completed
41 enrolled 7 charts
Dermatologic

Uveal Melanoma, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡